Loading…
Metropolis Healthcare (METROPOLIS)₹582.35+0.94%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), Metropolis Healthcare reported sales of ₹450 Cr, up 16.5% from Jun 2025, and net profit of ₹56.75 Cr, up 26.6% year on year. For the year to Mar 2026, sales were ₹1,646 Cr and net profit ₹190 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 308 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 |
| Expenses | 235 | 227 | 252 | 236 | 261 | 252 | 284 | 297 | 322 | 312 | 318 | 340 |
| Operating Profit | 75.12 | 65.14 | 80.19 | 79.17 | 90.22 | 72.16 | 62.11 | 90.13 | 108 | 95.27 | 108 | 111 |
| OPM % | 24.0% | 22.0% | 23.9% | 24.9% | 25.9% | 22.0% | 17.9% | 22.9% | 25.0% | 23.0% | 24.9% | 24.9% |
| Other Income | 0.99 | 1.99 | 2.99 | 1.99 | 2.99 | 2.99 | 6.99 | 7.99 | 0.99 | 0.00 | 7.99 | 4.99 |
| Interest | 5.99 | 4.99 | 5.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 5.99 | 5.99 | 7.99 | 5.99 |
| Depreciation | 21.95 | 24.93 | 25.96 | 25.93 | 26.96 | 27.95 | 28.93 | 30.95 | 31.92 | 31.95 | 38.93 | 31.91 |
| Profit before tax | 47.88 | 36.94 | 50.84 | 50.87 | 60.84 | 41.93 | 35.91 | 60.89 | 70.88 | 56.88 | 69.85 | 77.84 |
| Tax % | 26.0% | 26.0% | 28.0% | 25.0% | 24.0% | 26.0% | 19.0% | 26.0% | 26.0% | 26.0% | 27.0% | 27.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −7.02 | 0.00 | 0.00 |
| Net Profit | 35.88 | 26.89 | 36.83 | 37.87 | 46.83 | 30.89 | 28.90 | 44.81 | 52.77 | 41.86 | 50.77 | 56.75 |
| EPS (Rs) | 1.74 | 1.34 | 1.79 | 1.86 | 2.28 | 1.54 | 1.42 | 2.18 | 2.55 | 2.01 | 2.47 | 2.74 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 475 | 545 | 647 | 761 | 855 | 998 | 1,227 | 1,148 | 1,208 | 1,332 | 1,646 | 1,710 |
| Expenses | 360 | 406 | 469 | 561 | 621 | 710 | 884 | 859 | 924 | 1,028 | 1,245 | 1,293 |
| Operating Profit | 116 | 140 | 181 | 203 | 238 | 291 | 348 | 294 | 289 | 309 | 407 | 423 |
| OPM % | 24.0% | 26.0% | 27.9% | 26.9% | 27.9% | 28.9% | 27.9% | 25.9% | 23.9% | 22.9% | 24.9% | 24.7% |
| Other Income | 28.95 | 38.95 | 5.99 | 7.99 | −16.99 | 11.99 | 33.99 | 14.99 | 8.99 | 14.99 | 15.99 | 13.97 |
| Interest | 1.99 | 1.99 | 3.99 | 3.99 | 12.98 | 11.97 | 24.94 | 31.96 | 27.93 | 23.95 | 28.95 | 25.96 |
| Depreciation | 16.97 | 16.97 | 18.96 | 19.95 | 38.90 | 45.90 | 62.91 | 88.86 | 93.86 | 109 | 134 | 135 |
| Profit before tax | 128 | 160 | 164 | 187 | 169 | 243 | 293 | 188 | 174 | 191 | 258 | 275 |
| Tax % | 36.0% | 33.0% | 32.0% | 34.0% | 24.0% | 25.0% | 27.0% | 24.0% | 26.0% | 24.0% | 26.0% | — |
| Exceptional items | 7.02 | 9.02 | 1.01 | 2.01 | −17.06 | 0.00 | 12.04 | 0.00 | 1.01 | 9.03 | −4.01 | −7.02 |
| Net Profit | 81.64 | 107 | 112 | 124 | 127 | 182 | 214 | 142 | 127 | 145 | 190 | 202 |
| EPS (Rs) | 20.17 | 26.70 | 27.40 | 6.01 | 6.31 | 8.99 | 10.50 | 7.01 | 6.26 | 7.03 | 9.21 | 9.77 |
| Dividend payout % | 100.1% | 49.1% | 0.0% | 55.1% | 32.1% | 22.1% | 19.1% | 29.0% | 16.0% | 0.0% | 55.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.00 | 10.02 | 10.01 | 10.01 | 9.99 | 9.99 | 10.00 | 9.99 | 10.00 | 10.00 | 9.99 | 40.98 |
| Reserves | 352 | 269 | 314 | 405 | 408 | 512 | 696 | 876 | 977 | 1,085 | 1,319 | 1,471 |
| Borrowings | 13.99 | 5.01 | 1.01 | 1.01 | 17.99 | 66.94 | 112 | 379 | 266 | 197 | 204 | 232 |
| Other Liabilities | 86.58 | 107 | 187 | 109 | 112 | 159 | 180 | 255 | 239 | 253 | 322 | 384 |
| Total Liabilities | 461 | 391 | 511 | 525 | 549 | 749 | 999 | 1,519 | 1,493 | 1,544 | 1,856 | 2,128 |
| Fixed Assets | 153 | 142 | 202 | 207 | 213 | 295 | 342 | 1,058 | 1,119 | 1,174 | 1,444 | 1,598 |
| CWIP | 0.00 | 1.01 | 1.01 | 0.00 | 6.01 | 3.01 | 0.00 | 6.01 | 20.03 | 0.00 | 0.00 | 0.00 |
| Investments | 168 | 101 | 142 | 102 | 33.01 | 14.01 | 10.01 | 15.99 | 14.99 | 55.02 | 70.99 | 142 |
| Other Assets | 141 | 147 | 167 | 216 | 298 | 436 | 646 | 439 | 340 | 316 | 341 | 387 |
| Inventories | 17.94 | 15.93 | 13.94 | 20.92 | 25.89 | 23.90 | 40.87 | 50.81 | 44.81 | 38.86 | 47.86 | 44.83 |
| Trade receivables | 71.17 | 70.21 | 80.25 | 101 | 137 | 128 | 123 | 136 | 122 | 126 | 148 | 171 |
| Cash & equivalents | 28.89 | 33.87 | 40.81 | 59.74 | 79.67 | 209 | 419 | 166 | 92.64 | 70.72 | 48.84 | 61.76 |
| Total Assets | 461 | 391 | 511 | 525 | 549 | 749 | 999 | 1,519 | 1,493 | 1,544 | 1,856 | 2,128 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 69.08 | 91.10 | 102 | 104 | 90.05 | 215 | 249 | 253 | 247 | 264 | 263 | 351 |
| Cash from investing activity | −55.96 | 95.88 | −85.99 | 0.99 | 35.99 | −104 | 62.91 | −735 | 47.99 | −88.97 | −199 | −220 |
| Cash from financing activity | −9.01 | −174 | −17.01 | −87.01 | −118 | −54.95 | −33.01 | 163 | −292 | −181 | −86.96 | −115 |
| Net cash flow | 3.99 | 13.95 | −0.99 | 17.94 | 7.97 | 55.80 | 278 | −320 | 2.99 | −5.98 | −22.93 | 14.95 |
| Capex | 24.04 | 18.04 | 58.11 | 16.02 | 24.03 | 36.04 | 28.06 | 31.03 | 53.09 | 64.15 | 69.09 | 51.11 |
| Free cash flow | 45.85 | 78.78 | 44.87 | 89.75 | 66.80 | 179 | 220 | 223 | 195 | 199 | 196 | 299 |
| CFO / OP % | 87.0% | 113.0% | 109.0% | 89.0% | 78.0% | 118.0% | 106.0% | 96.0% | 102.0% | 105.0% | 98.9% | 98.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 57 | 54 | 54 | 57 | 66 | 55 | 45 | 40 | 39 | 38 | 41 | 38 |
| Inventory days | 53 | 47 | 39 | 54 | 56 | 45 | 60 | 69 | 65 | 59 | 66 | 52 |
| Days payable | 93 | 97 | 98 | 89 | 91 | 153 | 161 | 137 | 137 | 151 | 172 | 147 |
| Cash conversion cycle | 17 | 3 | −5 | 21 | 30 | −54 | −56 | −29 | −33 | −53 | −65 | −57 |
| Working capital days | 31 | 7 | −28 | 27 | 32 | 1 | −10 | −27 | −23 | −17 | −19 | −16 |
| ROCE % | 28.0% | 34.0% | 46.0% | 43.0% | 43.0% | 40.0% | 36.0% | 29.0% | 17.0% | 16.0% | 15.0% | 18.0% |
For the Jun 2026 quarter, Metropolis Healthcare reported sales of ₹450 Cr, up 16.5% year on year and net profit of ₹56.75 Cr, up 26.6% year on year. The operating margin was 24.9%.
Metropolis Healthcare's sales for the year to Mar 2026 were ₹1,646 Cr; over the last twelve months they were ₹1,710 Cr.
Net profit for the year to Mar 2026 was ₹190 Cr, and ₹202 Cr over the last twelve months. Earnings per share over the same trailing period were ₹9.77.
Metropolis Healthcare reported borrowings of ₹232 Cr at Mar 2026, against cash and equivalents of ₹61.76 Cr.
Cash from operations was ₹351 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹299 Cr.